Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.
Saved in:
| Title: | Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial. |
|---|---|
| Authors: | Kater AP; Department of Hematology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; Department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands; Lymphoma and Myeloma Center Amsterdam and Cancer Center Amsterdam, Amsterdam, Netherlands. Electronic address: a.p.kater@amsterdamumc.nl., Kersting S; Department of Hematology, Haga Hospital, The Hague, Netherlands., Dubois JM; Department of Hematology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; Department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands., van der Holt B; HOVON Foundation, Rotterdam, Netherlands; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., da Cunha-Bang C; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Te Raa D; Department of Internal Medicine, Gelderland Valley Hospital, Ede, Netherlands., Idink C; Department of Internal Medicine, ZorgSaam, Terneuzen, Netherlands., de Boer F; Department of Internal Medicine, Ikazia Hospital, Rotterdam, Netherlands., Droogendijk J; Department of Internal Medicine, Elisabeth-Tweesteden Hospital, Tilburg, Netherlands., de Heer K; Department of Internal Medicine, Flevoziekenhuis, Almere, Netherlands., van der Burg L; Department of Internal Medicine, Antonius Hospital, Sneek, Netherlands., Nijziel MR; Department of Internal Medicine, Catharina Hospital, Eindhoven, Netherlands., Tick L; Department of Internal Medicine, Máxima Medisch Centrum, Eindhoven, Netherlands., Levenga H; Department of Internal Medicine, Groene Hart Hospital, Gouda, Netherlands., Silbermann M; Department of Internal Medicine, Tergooi Hospital, Hilversum, Netherlands., Ludwig I; Department of Hematology, Bernhoven Hospital, Uden, Netherlands., Beeker A; Department of Internal Medicine, Spaarne Hospital, Hoofddorp, Netherlands., Bellido M; University Medical Center Groningen and University of Groningen, Groningen, Netherlands., Dobber JA; Department of Hematology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands., Evers LM; Department of Hematology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands., van der Kevie-Kersemaekers AM; Department of Human Genetics, Amsterdam University Medical Centers, Amsterdam, Netherlands., Mellink C; Department of Human Genetics, Amsterdam University Medical Centers, Amsterdam, Netherlands., Meulendijks I; HOVON Foundation, Rotterdam, Netherlands., Cunha S; HOVON Foundation, Rotterdam, Netherlands., Abrahamse-Testroote M; HOVON Foundation, Rotterdam, Netherlands., Zwezerijnen G; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, Netherlands., Zijlstra J; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, Netherlands., Niemann CU; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands. |
| Source: | The Lancet. Haematology [Lancet Haematol] 2025 Dec; Vol. 12 (12), pp. e935-e945. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Multicenter Study |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
